UroToday

ASTRO 2025: Interim Analysis of a Phase 2 Single Arm Trial of Extended Lymph Node Proton Irradiation for High Risk Prostate Cancer

(UroToday.com) The 67 th American Society for Radiation Oncology (ASTRO) annual meeting held in San Francisco between September 28 and September 30 was host to the Session QP 13 - GU 7: Quick Pitch: ...
UroToday

ASTRO 2025: Discussant – Bladder and Post-Prostatectomy Radiation

Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in the post-prostatectomy setting. This pre-planned secondary analysis of ...
UroToday

ASTRO 2025: Trials in Progress: CONSOLIDATE – Concurrent Radiotherapy with Enfortumab vedotin for Locally Advanced Bladder Cancer

(UroToday.com) The 2025 ASTRO annual meeting featured a bladder cancer trials in progress session and a presentation by Dr. Patrick Carriere discussing CONSOLIDATE, a study assessing concurrent ...
UroToday

ASTRO 2025: Digital Pathology-based Multimodal Artificial Intelligence Biomarker Models in Oligometastatic Castration-sensitive Prostate Cancer

(UroToday.com) The 67 th American Society for Radiation Oncology (ASTRO) annual meeting held in San Francisco between September 28 and September 30 was host to the Session EDU 34 - ROBIN ...
UroToday

ASTRO 2025: Radiation Oncology-Biology Integration Network (ROBIN) -Oligometastasis Center

The U54 ROBIN consortium is a first-of-its-kind effort to study the biological effects of radiation before, during, and after treatment, using small study cohorts for detailed molecular ...